John Stamos, the Emmy-nominated actor and producer known for his role on “Full House,” will receive the Bob Saget Legacy…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Treatment guidelines for scleroderma (SSc) have evolved since the turn of the century with advances in scientific understanding and…
People with scleroderma who are triple autoantibody-negative — meaning they don’t have three common disease-associated antibodies — are more…
Researchers have identified a molecular pathway in specific skin cells called keratinocytes that may be involved in inflammation and scarring…
Autologous stem cell transplant (ASCT), a procedure that essentially aims to reset the immune system, was effective for controlling…
Through an analysis of genetic data, scientists have identified dozens of existing medications that could potentially be repurposed as treatments…
Levels of soluble CD13, the circulating form of a protein involved in inflammation and fibrosis (scarring), are generally higher in…
Macrophages, a type of immune cell, may be mainly responsible for driving fibrosis, or scarring, in people with scleroderma,…
Carbon dioxide ablative fractional laser (CO2-AFL) therapy, a treatment that’s long been used to remove wrinkles, may help reduce skin…
The molecular signaling pathway EGFR-STAT1 is key for driving fibrosis (scarring) in scleroderma, according to a new study. The…